Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18617791 | 1.00 | BTK (0.54) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL16748085 | 1.00 | BTK (0.54) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL26180602 | 0.89 | BTK (0.59) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL22084628 | 0.89 | BTK (0.59) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL22084011 | 0.89 | BTK (0.59) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL23912295 | 0.89 | BTK (0.59) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL28527474 | 0.86 | BTK (0.56) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL22957939 | 0.86 | BTK (0.69) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL20737119 | 0.86 | BTK (0.69) | BTKNFKB1NFKB2RELACTSK | |
| SCHEMBL3195971 | 0.85 | BTK (0.54) | BTKNFKB1NFKB2RELACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388568-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4551549-A1 | NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010772-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388568-A1 | NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | BTK 1556/4885NFKB1 207/4885NFKB2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.